Chromosomal Microarray Analysis as a First-Tier Clinical Diagnostic Test in Patients With Developmental Delay/Intellectual Disability, Autism Spectrum Disorders, and Multiple Congenital Anomalies: A Prospective Multicenter Study in Korea
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background: To validate the clinical application of chromosomal microarray analysis (CMA) as a first-tier clinical diagnostic test and to determine the impact of CMA results on patient clinical management, we conducted a multicenter prospective study in Korean patients diagnosed as having developmental delay/intellectual disability (DD/ID), autism spectrum disorders (ASD), and multiple congenital anomalies (MCA). Methods: We performed both CMA and G-banding cytogenetics as the first-tier tests in 617 patients. To determine whether the CMA results directly influenced treatment recommendations, the referring clinicians were asked to complete a 39-item questionnaire for each patient separately after receiving the CMA results. Results: A total of 122 patients (19.8%) had abnormal CMA results, with either pathogenic variants (N=65) or variants of possible significance (VPS, N=57). Thirty-five well-known diseases were detected: 16p11.2 microdeletion syndrome was the most common, followed by Prader–Willi syndrome, 15q11-q13 duplication, Down syndrome, and Duchenne muscular dystrophy. Variants of unknown significance (VUS) were discovered in 51 patients (8.3%). VUS of genes putatively associated with developmental disorders were found in five patients: IMMP2L deletion, PTCH1 duplication, and ATRNL1 deletion. CMA results influenced clinical management, such as imaging studies, specialist referral, and laboratory testing in 71.4% of patients overall, and in 86.0%, 83.3%, 75.0%, and 67.3% of patients with VPS, pathogenic variants, VUS, and benign variants, respectively. Conclusions: Clinical application of CMA as a first-tier test improves diagnostic yields and the quality of clinical management in patients with DD/ID, ASD, and MCA.
Abstract
Background: To validate the clinical application of chromosomal microarray analysis (CMA) as a first-tier clinical diagnostic test and to determine the impact of CMA results on patient clinical management, we conducted a multicenter prospective study in Korean patients diagnosed as having developmental delay/intellectual disability (DD/ID), autism spectrum disorders (ASD), and multiple congenital anomalies (MCA). Methods: We performed both CMA and G-banding cytogenetics as the first-tier tests in 617 patients. To determine whether the CMA results directly influenced treatment recommendations, the referring clinicians were asked to complete a 39-item questionnaire for each patient separately after receiving the CMA results. Results: A total of 122 patients (19.8%) had abnormal CMA results, with either pathogenic variants (N=65) or variants of possible significance (VPS, N=57). Thirty-five well-known diseases were detected: 16p11.2 microdeletion syndrome was the most common, followed by Prader–Willi syndrome, 15q11-q13 duplication, Down syndrome, and Duchenne muscular dystrophy. Variants of unknown significance (VUS) were discovered in 51 patients (8.3%). VUS of genes putatively associated with developmental disorders were found in five patients: IMMP2L deletion, PTCH1 duplication, and ATRNL1 deletion. CMA results influenced clinical management, such as imaging studies, specialist referral, and laboratory testing in 71.4% of patients overall, and in 86.0%, 83.3%, 75.0%, and 67.3% of patients with VPS, pathogenic variants, VUS, and benign variants, respectively. Conclusions: Clinical application of CMA as a first-tier test improves diagnostic yields and the quality of clinical management in patients with DD/ID, ASD, and MCA.
참고문헌 (32)
- Girirajan S, "Human copy number variation and complex genetic disease", Annu Rev Genet, 45, pp.203~226 (2011)
- Miller DT, "Consensus statement : chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies", Am J Hum Genet, 86, pp.749~764 (2010)
- Manning M, "Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities", Genet Med, 12, pp.742~745 (2010)
- Sanmann JN, "Assessing the utility of confirmatory studies following identification of large-scale genomic imbalances by microarray", Genet Med, 17, pp.875~879 (2015)
- Haddow JE, "Human genome epidemiology: a scientific foundation for using genetic information to improve health and prevent disease", pp.217~233 (2004), Oxford University Press
- Henderson LB, "The impact of chromosomal microarray on clinical management : a retrospective analysis", Genet Med, 16, pp.657~664 (2014)
- Riggs ER, "Chromosomal microarray impacts clinical management", Clin Genet, 85, pp.147~153 (2014)
- Coulter ME, "Chromosomal microarray testing influences medical management", Genet Med, 13, pp.770~776 (2011)
- Tonelli M, "Recommendations on screening for developmental delay", CMAJ, 188, pp.579~587 (2016)
- Council on Children with Disabilities, "Identifying infants and young children with developmental disorders in the medical home : an algorithm for developmental surveillance and screening", Pediatrics, 118, pp.405~420 (2006)
- McGowan-Jordan J, "ISCN : an international system for human cytogenomic nomenclature" (2016), Karger
- Kearney HM, "American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants", Genet Med, 13, pp.680~685 (2011)
- Bartnik M, "The usefulness of array comparative genomic hybridization in clinical diagnostics of intellectual disability in children", Dev Period Med, 18, pp.307~317 (2014)
- Cappuccio G, "New insights in the interpretation of array-CGH : autism spectrum disorder and positive family history for intellectual disability predict the detection of pathogenic variants", Ital J Pediatr, 42, pp.39~ (2016)
- Ozyilmaz B, "Experiences in microarray-based evaluation of developmental disabilities and congenital anomalies", Clin Genet, 92, pp.372~379 (2017)
- Xiang B, "Genome-wide oligonucleotide array comparative genomic hybridization for etiological diagnosis of mental retardation : a multicenter experience of 1499 clinical cases", J Mol Diagn, 12, pp.204~212 (2010)
- 신새암, "Routine Chromosomal Microarray Analysis is Necessary in Korean Patients With Unexplained Developmental Delay", Mental Retardation, Annals of Laboratory Medicine, pp.2015, 35(5)[DOI]
- Glancy M, "Transmitted duplication of 8p23.1-8p23.2 associated with speech delay, autism and learning difficulties", Eur J Hum Genet, 17, pp.37~43 (2009)
- Harada N, "Duplication of 8p23.2: a benign cytogenetic variant?", Am J Med Genet, 111, pp.285~288 (2002)
- Rehm HL, "ClinGen–the Clinical Genome Resource", N Engl J Med, 372, pp.2235~2242 (2015)
- Bertelsen B, "Intragenic deletions affecting two alternative transcripts of the IMMP2L gene in patients with Tourette syndrome", Eur J Hum Genet, 22, pp.1283~1289 (2014)
- Gimelli S, "Interstitial 7q31.1 copy number variations disrupting IMMP2L gene are associated with a wide spectrum of neurodevelopmental disorders", Mol Cytogenet, 7, pp.54~ (2014)
- Derwińska K, "PTCH1 duplication in a family with microcephaly and mild developmental delay", Eur J Hum Genet, 17, pp.267~271 (2009)
- Stark Z, "De novo 325 kb microdeletion in chromosome band 10q25.3 including ATRNL1 in a boy with cognitive impairment, autism and dysmorphic features", Eur J Med Genet, 53, pp.337~339 (2010)
- Shoukier M, "Array CGH in patients with developmental delay or intellectual disability : are there phenotypic clues to pathogenic copy number variants", Clin Genet, 83, pp.53~65 (2013)
- 이차곤, "Array-Based Comparative Genomic Hybridization in 190 Korean Patients with Developmental Delay and", or Intellectual Disability: A Single Tertiary Care University Center Study, 2013, pp.54(6), 1463~1470[DOI]
- Hayeems RZ, "Capturing the clinical utility of genomic testing : medical recommendations following pediatric microarray", Eur J Hum Genet, 23, pp.1135~1141 (2015)
- Saam J, "How physicians use array comparative genomic hybridization results to guide patient management in children with developmental delay", Genet Med, 10, pp.181~186 (2008)
- Nevado J, "New microdeletion and microduplication syndromes : a comprehensive review", Genet Mol Biol, 37, pp.210~219 (2014)
- Weise A, "Microdeletion and microduplication syndromes", J Histochem Cytochem, 60, pp.346~358 (2012)
- Trujillano D, "Clinical exome sequencing : results from 2819 samples reflecting 1000 families", Eur J Hum Genet, 25, pp.176~182 (2017)
- Grozeva D, "Targeted next-generation sequencing analysis of 1, 000 individuals with intellectual disability", Hum Mutat, 36, pp.1197~1204 (2015)